Recent Updates
Recently added Catalysts
INO Negative Sentiment Score: 20/100

Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – INO

Key Takeaway: Inovio Pharmaceuticals, Inc. is facing a securities class action lawsuit from shareholders who purchased stock during the specified class period. The lawsuit alleges that the company made materially false or misleading statements related to its CELLECTRA device and the regulatory status of its lead product candidate, INO-3107. It claims that manufacturing deficiencies and insufficient information impacted the prospects for FDA submission and approval. Shareholders are encouraged to register for participation in the legal proceedings by the April 7, 2026 deadline.

Market Sentiment Analysis

CONCERNS & RISKS

  • Inovio is being sued for securities law violations which may indicate deeper financial issues.
  • Allegations include misleading statements regarding the quality of their CELLECTRA device's manufacturing.
  • Concerns about the likelihood of submitting INO-3107 for FDA review on time.
  • Overall regulatory and commercial prospects for INO-3107 were allegedly overstated.

Full Press Release Details

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).
Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 10, 2023 to December 26, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: April 7, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form-2/?id=184113&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of INO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Inovio Pharmaceuticals?

The class period for Inovio Pharmaceuticals is from October 10, 2023, to December 26, 2025.

What allegations are made against Inovio Pharmaceuticals?

Allegations include manufacturing deficiencies and misleading statements about the INO-3107 BLA.

When is the deadline to become a lead plaintiff?

The deadline to seek lead plaintiff status is April 7, 2026.

How can shareholders participate in the class action?

Shareholders can register through the provided link to participate in the class action.

What services does the Gross Law Firm provide?

The Gross Law Firm helps investors recover losses from deceit and fraudulent practices.

Last updated: Mar 6, 2026